Citigroup Lowers Evolent Health (NYSE:EVH) Price Target to $4.00

Evolent Health (NYSE:EVH) had its price objective lowered by equities research analysts at Citigroup from $6.00 to $4.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the technology company’s stock. Citigroup’s target price would suggest a potential upside of 19.94% from the company’s current price.

A number of other equities research analysts have also recently commented on EVH. Royal Bank Of Canada dropped their target price on Evolent Health from $5.00 to $3.00 and set a “sector perform” rating on the stock in a research report on Wednesday. Canaccord Genuity Group dropped their price objective on Evolent Health from $16.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 14th. Stephens raised Evolent Health from an “equal weight” rating to an “overweight” rating and set a $7.00 target price for the company in a research note on Thursday, November 13th. KeyCorp cut shares of Evolent Health from an “overweight” rating to a “sector weight” rating in a research note on Wednesday. Finally, JPMorgan Chase & Co. cut their price target on shares of Evolent Health from $13.00 to $7.00 and set an “overweight” rating for the company in a report on Monday, November 17th. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $6.50.

Evolent Health Stock Performance

EVH traded up $0.20 during midday trading on Thursday, hitting $3.34. 4,017,498 shares of the company were exchanged, compared to its average volume of 3,108,708. The firm has a market capitalization of $372.19 million, a price-to-earnings ratio of -0.65 and a beta of 0.27. The company’s 50 day simple moving average is $3.52 and its 200 day simple moving average is $5.85. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 1.25. Evolent Health has a 1-year low of $2.50 and a 1-year high of $12.06.

Evolent Health (NYSE:EVH) last posted its earnings results on Tuesday, February 24th. The technology company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.06 by $0.02. Evolent Health had a positive return on equity of 1.30% and a negative net margin of 28.49%.The firm had revenue of $468.72 million for the quarter, compared to analyst estimates of $468.48 million. During the same period last year, the company earned ($0.02) earnings per share. Evolent Health’s revenue for the quarter was down 27.5% compared to the same quarter last year. As a group, sell-side analysts predict that Evolent Health will post 0.08 earnings per share for the current year.

Hedge Funds Weigh In On Evolent Health

Institutional investors and hedge funds have recently bought and sold shares of the company. Brighton Jones LLC acquired a new stake in shares of Evolent Health during the fourth quarter valued at about $3,927,000. Geode Capital Management LLC boosted its position in shares of Evolent Health by 3.1% during the second quarter. Geode Capital Management LLC now owns 2,667,642 shares of the technology company’s stock worth $30,041,000 after buying an additional 80,155 shares during the period. Walleye Capital LLC grew its stake in shares of Evolent Health by 1,198.0% in the second quarter. Walleye Capital LLC now owns 647,761 shares of the technology company’s stock valued at $7,294,000 after buying an additional 597,858 shares in the last quarter. Edgestream Partners L.P. purchased a new position in Evolent Health in the second quarter valued at $2,587,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in Evolent Health by 79.1% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 403,677 shares of the technology company’s stock worth $4,545,000 after purchasing an additional 178,307 shares during the period.

Key Stories Impacting Evolent Health

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Q4 results topped expectations — Evolent reported $0.08 EPS vs. $0.06 consensus and revenue of $468.7M (in line). The beat and the company’s commentary on execution are a near-term bullish trigger. Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results (PR Newswire)
• Positive Sentiment: Earnings call highlighted strong oncology growth and strategic wins — management pointed to market-share gains, strong renewal rates and continued migration to enhanced Performance Suite contracts, supporting medium-term revenue opportunities. Q4 2025 Earnings Call Transcript (Seeking Alpha)
• Positive Sentiment: BTIG left a buy rating and set a new $8.00 target (down from $10) — still implies significant upside versus current levels and signals at least one institutional view that upside remains after the quarter. BTIG Research price target note
• Neutral Sentiment: FY2026 revenue guidance of $2.4B–$2.6B was provided and sits around consensus — the range keeps expectations steady but does not materially change the near-term story. FY2026 guidance in PR
• Neutral Sentiment: Headline coverage notes a sharp intraday move — media and retail attention (e.g., Yahoo Finance) likely amplified trading volume and the price bounce. That can produce short-term spikes without changing fundamentals. Evolent Health Shares Skyrocket (Yahoo Finance)
• Negative Sentiment: Royal Bank of Canada cut its target to $3.00 and moved to “sector perform” — this downgrade to a lower target adds selling pressure and signals more cautious institutional views. RBC price target note
• Negative Sentiment: Needham sharply cut its target from $15 to $4 while keeping a buy — the large reduction reduces the peg for upside and suggests lowered expectations for near-term recovery. Needham price target note
• Negative Sentiment: KeyCorp downgraded EVH from overweight to sector weight — another institutional shift toward caution that can weigh on sentiment and limit short-term rallies. Analyst downgrade coverage (TickerReport)

Evolent Health Company Profile

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.